Pharma Focus Asia

Aurigene Pharmaceutical Services Opens New Biologics Facility in India


Aurigene Pharmaceutical Services is set to open a new biologics facility in India, providing process development and clinical-scale manufacturing capabilities.


This state-of-the-art facility boasts top-tier equipment and control systems, supported by a highly skilled talent pool, ensuring a seamless transition to large-scale commercial CGMP manufacturing facilities. Additionally, it will efficiently aid in the development of innovative medicines.

The facility is designed to support process and analytical development needs, as well as small-scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical trials.

Complementing the existing discovery capabilities and infrastructure, which mainly focuses on recombinant proteins such as monoclonal antibodies, bispecific and multispecific antibodies, immune-fusion molecules, antibody-drug conjugates, and other complex proteins. 

This new facility in Genome Valley will deliver robust, compliant, and economically viable cell lines, process development solutions, and supporting analytical methods to facilitate rapid entry and progression through clinical development stages.

The process and analytical development laboratories are now operational, with the manufacturing capacity set to be commissioned by the end of 2024.


Name    Aurigene Pharmaceutical Services  
Type      New Construction
Year       2024

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference